Table Graph
      published meta-analysis   sensitivity analysis   studies

anticoagulant, prophylactic dose in COVID-19 mild to moderate - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 (REV) 1.14 [0.83; 1.56] 1.14[0.83; 1.56]ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 (REV)10%2,226NAnot evaluable clinical improvement (28-day)detailed resultsATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 (REV) 0.79 [0.64; 0.98] 0.79[0.64; 0.98]ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 (REV)10%2,219NAnot evaluable death or ventilationdetailed resultsATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 (REV) 1.22 [0.94; 1.59] 1.22[0.94; 1.59]ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 (REV)10%2,231NAnot evaluable Major bleedingdetailed resultsATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 (REV) 0.56 [0.27; 1.13] 0.56[0.27; 1.13]ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients), 2021 (REV)10%2,227NAnot evaluable0.22.01.0relative treatment effectwww.metaEvidence.org2024-04-27 22:47 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 90 - treatments: 829 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons